Title: Efficacy and safety of serenoa repens extract among patients with benign prostatic hyperplasia in china: A multicenter, randomized, double blind, placebo controlled trial

Biography:

Duane Baldwin graduated from the Loma Linda University School of Medicine in 1991. He works in Loma Linda, CA and specializes in Urology. Dr. Baldwin is affiliated with Loma Linda University Medical Center and Loma Linda University Medical East.

Abstract

We conducted a double blind, placebo-controlled study of 354 patients with LUTS/BPH from 19 institutions, to evaluate the efficacy and safety of Serenoa repens. Participants were randomly assigned (1:1) into the Serenoa repens extract (320 mg) or placebo groups for 24 weeks. Primary efficacy parameters were changes in International Prostate Symptom Score and peak urinary flow from baseline to each assessment. Secondary efficacy parameters included improvement of storage symptom and voiding symptom scores, prostate volume, urinary frequency, and total prostate-specific antigen level. Other parameters assessed were quality of life score, a four‐item male sexual function questionnaire score, and International Index of Erectile Function score across the consecutive double-blind visits.